Erasca to Present at the Bank of America Securities Health Care Conference
Rhea-AI Summary
Erasca (Nasdaq: ERAS) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas. Management will take part in a fireside chat on Wednesday, May 13, 2026 at 3:00 pm PT and hold one-on-one investor meetings.
A live audio webcast will be available at Erasca.com/events, with an archived replay accessible for 30 days after the webcast.
Positive
- None.
Negative
- None.
News Market Reaction – ERAS
In the May 6 session, ERAS gained 9.11%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.2% during that session. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Clinical data update | Positive | -48.3% | Positive preliminary Phase 1 ERAS-0015 data in KRAS-mutant solid tumors. |
| Apr 27 | Conference call | Positive | -10.9% | Announcement of call and webcast to discuss ERAS-0015 Phase 1 data. |
| Mar 12 | Earnings update | Positive | -7.0% | Q4/FY25 results with strong cash of $341.8M and extended runway. |
| Mar 10 | Licensing expansion | Positive | -1.1% | Option exercised to secure worldwide rights for ERAS-0015, including China. |
| Mar 05 | Collaboration deal | Positive | +2.8% | Clinical collaboration with Tango to test ERAS-0015 plus vopimetostat. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive in tone, yet ERAS often traded down on these announcements, with only one of the last five events showing a positive next-day price reaction.
Over the past few months, ERAS has focused on advancing its pan-RAS molecular glue ERAS-0015, including a clinical collaboration with Tango and securing worldwide rights, alongside positive preliminary Phase 1 data reported on Apr 27, 2026. Despite constructive clinical and financial updates, the stock reacted negatively after most of these events. Today’s conference participation fits within an ongoing cadence of investor communication and clinical-progress updates.
Key Terms
ras/mapk pathway-driven cancers medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2026 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 pm Pacific Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
